1. Combination of G2-S16 dendrimer/dapivirine antiretroviral as a new HIV-1 microbicide.
- Author
-
Guerrero-Beltrán C, Prieto A, Leal M, Jiménez JL, and Muñoz-Fernández MÁ
- Subjects
- Animals, Anti-HIV Agents administration & dosage, Anti-HIV Agents toxicity, Bacteria, Anaerobic drug effects, Cell Line, Tumor, Cell Survival drug effects, Chlorocebus aethiops, Dendrimers administration & dosage, Dendrimers toxicity, Dose-Response Relationship, Drug, Drug Synergism, Epithelial Cells virology, HIV Infections prevention & control, Humans, Microbial Sensitivity Tests, Polyelectrolytes, Polymers, Pyrimidines administration & dosage, Pyrimidines toxicity, Silanes administration & dosage, Silanes toxicity, Vero Cells, Anti-HIV Agents pharmacology, Dendrimers pharmacology, Epithelial Cells drug effects, HIV-1 drug effects, Pyrimidines pharmacology, Silanes pharmacology
- Abstract
Aim: To research the synergistic activity of G2-S16 dendrimer and dapivirine (DPV) antiretroviral as microbicide candidate to prevent HIV-1 infection. Materials & methods: We assess the toxicity of DPV on cell lines by MTT assay, the anti-HIV-1 activity of G2-S16 and DPV alone or combined at several fixed ratios. Finally, their ability to inhibit the bacterial growth in vitro was assayed. The analysis of combinatorial effects and the effective concentrations were performed with CalcuSyn software. Conclusion: Our results represent the first proof-of-concept study of G2-S16/DPV combination to develop a safe microbicide.
- Published
- 2019
- Full Text
- View/download PDF